

Trypanosoma cruzi: Protective Immunity in Mice Immune to Infection
Is Associated with a T-Helper Type 1 Response

Experimental Parasitology

84, 156-167

DOI: [10.1006/expr.1996.0101](https://doi.org/10.1006/expr.1996.0101)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Long-Lived Protective Immunity to Listerials Conferred by Immunization with Particulate or Soluble Listerial Antigen Preparations Coadministered with IL-12. <i>Cellular Immunology</i> , 1998, 184, 92-104.	1.4	13
2	Activation of CD4+ and CD8+ parasite -specific T-cells by macrophages infected with live <i>T. Cruzi</i> amastigotes. <i>Immunology Letters</i> , 1998, 63, 97-105.	1.1	4
3	Serum cytokines in chronic Chagas' disease. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 1999, 32, 285-289.	0.4	12
4	The Cytostome of <i>Trypanosoma cruzi</i> Epimastigotes Is Associated with the Flagellar Complex. <i>Experimental Parasitology</i> , 1999, 92, 223-231.	0.5	28
5	The Cytoskeleton of Trypanosomatid Parasites. <i>Annual Review of Microbiology</i> , 1999, 53, 629-655.	2.9	271
6	Needle-free, non-adjuvanted skin immunization by electroporation-enhanced transdermal delivery of diphtheria toxoid and a candidate peptide vaccine against hepatitis B virus. <i>Vaccine</i> , 1999, 18, 517-523.	1.7	40
7	<i>Trypanosoma cruzi</i> , agent de la maladie de Chagas ou trypanosomose américaine. <i>Annales De L'Institut Pasteur / Actualités</i> , 1999, 10, 51-65.	0.1	0
8	DNA-Based Immunization with <i>Trypanosoma cruzi</i> Complement Regulatory Protein Elicits Complement Lytic Antibodies and Confers Protection against <i>Trypanosoma cruzi</i> Infection. <i>Infection and Immunity</i> , 2000, 68, 4986-4991.	1.0	73
9	CpG DNA as a Th1-promoting adjuvant in immunization against <i>Trypanosoma cruzi</i> . <i>Vaccine</i> , 2000, 19, 234-242.	1.7	43
10	Paraflagellar rod proteins administered with alum and IL-12 or recombinant adenovirus expressing IL-12 generates antigen-specific responses and protective immunity in mice against <i>Trypanosoma cruzi</i> . <i>Vaccine</i> , 2000, 18, 1419-1427.	1.7	28
11	IL-18 potentiates the adjuvant properties of IL-12 in the induction of a strong Th1 type immune response against a recombinant antigen. <i>Vaccine</i> , 2000, 18, 2002-2008.	1.7	36
12	Advances and prospects for subunit vaccines against protozoa of veterinary importance. <i>Veterinary Parasitology</i> , 2001, 101, 291-310.	0.7	95
13	Immunotherapy of <i>Trypanosoma Cruzi</i> Infections. <i>Current Drug Targets Immune, Endocrine and Metabolic Disorders</i> , 2002, 2, 247-254.	1.8	17
14	<i>Trypanosoma cruzi</i> : requirements for induction and maintenance of protective immunity conferred by immunization. <i>Experimental Parasitology</i> , 2002, 102, 89-98.	0.5	3
15	The immunogenicity of <i>Mycobacterium paratuberculosis</i> 85B antigen. <i>Medical Microbiology and Immunology</i> , 2002, 190, 179-187.	2.6	34
16	Immunization with recombinant paraflagellar rod protein induces protective immunity against <i>Trypanosoma cruzi</i> infection. <i>Vaccine</i> , 2003, 21, 3058-3069.	1.7	32
17	Relationship between the immune response and protection conferred by new designed inactivated vaccines against ovine enzootic abortion in a mouse model. <i>Vaccine</i> , 2003, 21, 3126-3136.	1.7	27
18	Humoral and Cellular Immune Responses to <i>Trypanosoma cruzi</i> -Derived Paraflagellar Rod Proteins in Patients with Chagas' Disease. <i>Infection and Immunity</i> , 2003, 71, 3165-3171.	1.0	41

#	ARTICLE	IF	CITATIONS
19	Brucella Lumazine Synthase Elicits a Mixed Th1-Th2 Immune Response and Reduces Infection in Mice Challenged with Brucella abortus 544 Independently of the Adjuvant Formulation Used. Infection and Immunity, 2003, 71, 5750-5755.	1.0	93
20	Balanced cytokine-producing pattern in mice immunized with an avirulent Trypanosoma cruzi. Anais Da Academia Brasileira De Ciencias, 2003, 75, 167-172.	0.3	8
21	Cell fractionation of parasitic protozoa: a review. Memorias Do Instituto Oswaldo Cruz, 2003, 98, 151-170.	0.8	14
22	Immunotherapy of Trypanosoma cruzi Infection with DNA Vaccines in Mice. Infection and Immunity, 2004, 72, 46-53.	1.0	99
23	Immunization with cytoplasmic repetitive antigen and flagellar repetitive antigen of Trypanosoma cruzi stimulates a cellular immune response in mice. Parasitology, 2004, 129, 563-570.	0.7	20
24	Humoral and cellular immune responses in BALB/c and C57BL/6 mice immunized with cytoplasmic (CRA) and flagellar (FRA) recombinant repetitive antigens, in acute experimental Trypanosoma cruzi infection. Parasitology Research, 2005, 96, 154-161.	0.6	19
25	Protective immunogenicity of the paraflagellar rod protein 2 of Leishmania mexicana. Vaccine, 2005, 23, 984-995.	1.7	29
26	The CC Chemokine Receptor 5 Is Important in Control of Parasite Replication and Acute Cardiac Inflammation following Infection with Trypanosoma cruzi. Infection and Immunity, 2006, 74, 135-143.	1.0	72
27	Comparative evaluation of therapeutic DNA vaccines against Trypanosoma cruzi in mice. FEMS Immunology and Medical Microbiology, 2007, 50, 333-341.	2.7	52
28	Use of proteoliposome as a vaccine against Trypanosoma cruzi in mice. Chemistry and Physics of Lipids, 2008, 152, 86-94.	1.5	10
29	Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis. Vaccine, 2008, 26, 1902-1911.	1.7	56
30	Expression of cytokines and chemokines and microvasculature alterations of the tongue from patients with chronic Chagas disease. Parasitology Research, 2009, 105, 1031-1039.	0.6	4
31	American Trypanosomiasis. , 2009, , 1423-1450.		8
32	The paraflagellar rod of kinetoplastid parasites: From structure to components and function. International Journal for Parasitology, 2010, 40, 135-148.	1.3	122
33	Vaccine Development Against Trypanosoma cruzi and Chagas Disease. Advances in Parasitology, 2011, 75, 121-146.	1.4	62
34	Advances and challenges towards a vaccine against Chagas disease. Hum Vaccin, 2011, 7, 1184-1191.	2.4	76
35	Leishmaniasis: Vaccine candidates and perspectives. Vaccine, 2012, 30, 3834-3842.	1.7	81
36	The Trypanosoma cruzi Flagellum Is Discarded via Asymmetric Cell Division following Invasion and Provides Early Targets for Protective CD8+ T Cells. Cell Host and Microbe, 2014, 16, 439-449.	5.1	44

#	ARTICLE	IF	CITATIONS
37	Experimental Vaccines against Chagas Disease: A Journey through History. Journal of Immunology Research, 2015, 2015, 1-8.	0.9	49
38	<p></p>Advances in nanocarriers as drug delivery systems in Chagas disease</p>. International Journal of Nanomedicine, 2019, Volume 14, 6407-6424.	3.3	31
39	Location and expression kinetics of Tc24 in different life stages of Trypanosoma cruzi. PLoS Neglected Tropical Diseases, 2021, 15, e0009689.	1.3	9
40	Immunization of Mice with a Tola-Like Surface Protein of <i>Trypanosoma cruzi</i> Generates CD4⁺T-Cell-Dependent Parasiticidal Activity. Infection and Immunity, 1999, 67, 4603-4612.	1.0	32
41	Immunization with the Recombinant Surface Protein rTcSP2 Alone or Fused to the CHP or ATPase Domain of TcHSP70 Induces Protection Against Acute Trypanosoma cruzi Infection. Journal of Vaccines & Vaccination, 2010, 01, .	0.3	5
43	Preclinical advances and the immunophysiology of a new therapeutic Chagas disease vaccine. Expert Review of Vaccines, 2022, 21, 1185-1203.	2.0	3